WALTHAM, Mass.--(BUSINESS WIRE)--Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provided an update on corporate activities during the quarter ended December 31, 2015.
“Cerulean is rapidly approaching a key inflection point, with top-line results from our randomized Phase 2 clinical trial of CRLX101 in combination with Avastin® (bevacizumab) in relapsed renal cell carcinoma expected in the first half of 2016,” said Christopher D. T. Guiffre, President & Chief Executive Officer of Cerulean.
